ArriVent BioPharma, Inc. 8K

ArriVent BioPharma reported Q2 2026 results, affirmed cash runway into 2028, and announced key clinical and licensing milestones across its firmonertinib, ARR-217, and ARR-002 oncology programs.

On August 12, 2026, ArriVent BioPharma, Inc. reported its unaudited financial results for the second quarter ended June 30, 2026 and provided a pipeline and corporate update, highlighting ongoing global pivotal Phase 3 trials of firmonertinib in first-line EGFR exon 20 insertion mutant and PACC mutant NSCLC, advancement of ARR-217 into Phase 1b dose optimization for gastrointestinal malignancies, expected first-patient dosing of ARR-002 in a Phase 1 trial for ovarian and endometrial cancers in Q3 2026, execution of an exclusive Greater China licensing agreement with Shanghai Allist Pharmaceuticals for ARR-002, and a cash and investment balance of $373.1 million expected to fund operations into 2028, alongside reporting a net loss of $93.2 million for the six months ended June 30, 2026.

Filing Facts

CIK

1868279

Ticker

AVBP

Form

8K

Source Type

fda

Accession

0001104659-26-094869

Alert Tier

6